Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 7, 2007, Pages 765-770

  Battiwalla, Minoo ^a   Wu, Yiyuan ^a   Bajwa, Rajinder P S ^a   Radovic, Marija ^a   Almyroudis, Nikolaos G ^a   Segal, Brahm H ^a   Wallace, Paul K ^a   Nakamura, Ryotaro ^b   Padmanabhan, Swaminathan ^a   Hahn, Theresa ^a   McCarthy Jr , Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Division of Hematology and Hematopoietic Cell Transplantation   (United States)

Author keywords

CMV; DNA polymerase; Ganciclovir

Indexed keywords

BROXURIDINE; FOSCARNET; GANCICLOVIR; TACROLIMUS; THYMIDINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; RAJI CELL;

ANTIVIRAL AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34250208050     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.03.009     Document Type: Article

References (24)

1. Meyers J.D., Flournoy N., and Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153 (1986) 478-488
2. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325 (1991) 1601-1607
3. Boeckh M., Bowden R.A., Gooley T., Myerson D., and Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93 (1999) 1781-1782
4. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., and Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
5. Bowden R.A., Digel J., Reed E.C., and Meyers J.D. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis 156 (1987) 899-903
6. Craddock C., Szydlo R.M., Dazzi F., et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 112 (2001) 228-236
7. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95 (2000) 2219-2225
8. Meijer E., Dekker A.W., Rozenberg-Arska M., Weersink A.J., and Verdonck L.F. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 35 (2002) 703-712
9. Nichols W.G., Corey L., Gooley T., Davis C., and Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002) 273-282
10. Cheng Y.C., Huang E.S., Lin J.C., et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 80 (1983) 2767-2770
11. Sommadossi J.P., and Carlisle R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 31 (1987) 452-454
12. Hamzeh F.M., and Lietman P.S. Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother 35 (1991) 1818-1823
13. Reid R., Mar E.C., Huang E.S., and Topal M.D. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem 263 (1988) 3898-3904
14. Freitas V.R., Smee D.F., Chernow M., Boehme R., and Matthews T.R. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother 28 (1985) 240-245
15. Reusser P., Einsele H., Lee J., et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002) 1159-1164
16. Crumpacker C.S. Mechanism of action of foscarnet against viral polymerases. Am J Med 92 (1992) 3S-7S
17. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 40 (1989) 213-285
18. Quinnan Jr. G.V., Burns W.H., Kirmani N., et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis 6 (1984) 156-163
19. Reusser P., Riddell S.R., Meyers J.D., and Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78 (1991) 1373-1380
20. Gratama J.W., van Esser J.W., Lamers C.H., et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98 (2001) 1358-1364
21. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., and Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 (1994) 1971-1979
22. Nakamura R., Battiwalla M., Solomon S., et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10 (2004) 49-57
23. Prentice H.G., Gluckman E., Powles R.L., et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 343 (1994) 749-753
24. Prentice H.G., Gluckman E., Powles R.L., et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant 19 (1997) 129-133